Biotie Names Chris Piggott as Chief Business Officer
Biotie Therapies Corp. announced the appointment of Chris Piggott as Chief Business Officer and member of the Management Team of the Company, effective June 1, 2009. Mr. Piggott is replacing Kai Lähdesmäki, previously the Company's Vice President, business development, who retired from the Company in 2007 and continues to serve as an advisor for Biotie. Mr. Piggott has more than 30 years of experience in the pharmaceutical industry and a proven track record in establishing and implementing business development strategies in addition to executing deals between large, medium and small companies in Europe, the United States and Asia.
Mr. Piggott spent over 25 years with sanofi-aventis and its predecessor companies including Aventis Pharma, Marion Merrell Dow and Hoechst Marion Roussel. During his tenure, Mr. Piggott managed Aventis' licensing activities with companies based in Japan and Korea while also supporting the company's respiratory, anti-infective, Alzheimer's disease research groups, and led a team in the oncology field. Mr. Piggott also successfully negotiated and executed license, co-development and co-promotion agreements with Altana Pharma (now Nycomed) for ciclesonide and secured rights through licensing and research agreements to Coley Pharmaceuticals' CpG oligonucleotides in the respiratory field. He also led negotiations resulting in the licensing of a Japanese Alzheimer's disease treatment. Most recently, Mr. Piggott established and managed a business intelligence group dedicated to supporting corporate development activities at sanofi-aventis from 2005 to 2007.
Other news from the department people
